Core Viewpoint - Tianmao Group, controlled by Liu Yiqian, has voluntarily delisted from the A-share market after 29 years due to continuous losses at its subsidiary, Guohua Life Insurance, and difficulties in disclosing its 2024 annual report [2][9]. Company History - Tianmao Group was originally established as Zhongtian Co., Ltd. in November 1993 and was later renamed Baike Pharmaceutical before becoming Tianmao Group in 2006 [3][5]. - Liu Yiqian became the largest shareholder of Baike Pharmaceutical in 2001, acquiring 28.97% of the shares for 206 million [3]. Financial Performance - Tianmao Group's performance improved significantly after acquiring 51% of Guohua Life in 2015, with revenue soaring to 16.99 billion in 2016, a 14-fold increase, and a net profit of 1.779 billion [5]. - However, Guohua Life faced declining profitability from 2020 to 2023, with net profits dropping from 1.11 billion to a loss of 1.155 billion in 2023 [8][9]. Regulatory Challenges - The company has been under investigation by the China Securities Regulatory Commission (CSRC) for failing to disclose its annual report on time, leading to its eventual delisting [9][10]. - Guohua Life's solvency ratios fell below regulatory requirements, prompting significant capital injections and raising concerns about its financial health [6][8]. Delisting Process - Tianmao Group submitted its application for voluntary delisting on September 4, 2025, and the Shenzhen Stock Exchange decided to terminate its listing on September 25, 2025, with the actual delisting occurring on September 30, 2025 [9][10]. Investor Concerns - Investors have raised concerns regarding the low cash option price of 1.60 per share, which is significantly below the net asset value of 4.41 per share, leading to accusations of market manipulation [10][11]. - The stock price of Tianmao Group has dropped over 50% since the announcement of its annual report difficulties, from 3.38 to 1.45 per share [11].